Kevin Kwei

Kevin Kwei is a seasoned professional in the field of translational medicine and biomarker research, currently serving as Sr. Director of Translational Medicine at FibroGen, Inc. Previously, Kevin held significant roles including VP of Biomarker and Translational Research at Kartos Therapeutics, Inc., and Senior Director of Biomarker Sciences at Biosplice Therapeutics. Additional experience includes serving as a Director of Translational Medicine and Senior Scientist in Clinical Genetics at Pharmacyclics, an AbbVie Company, as well as working as a Biomarker Consultant at Annexon Biosciences. Kevin Kwei earned a PhD in Cancer Biology from the University of Arizona and a B.S. in Molecular Biology from the University of Wisconsin-Madison.